In addition to KIT and KRAS, there was an over-representation of mutations in cell division cycle 27 (CDC27) (11.9%; 5 mutations, 5 tumours) and PRKRIR (4 mutations, 2 tumours), neither of which have been previously reported as TGCT drivers. Here, KRAS is linked to neoplasm.